Inhibition of AXL ameliorates pulmonary fibrosis via attenuation of M2 macrophage polarisation
European Respiratory Journal · 2025-06 · 65 (6) · 2400615
DOI: 10.1183/13993003.00615-2024 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Respiratory Journal, online erschienen am 09.01.2025. Verfasst von Dong Ha Kim und 18 weiteren Autor:innen. Beteiligte Einrichtung: Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. Hauptthemen laut MEDLINE: Receptor Protein-Tyrosine Kinases, Proto-Oncogene Proteins, Macrophages, Idiopathic Pulmonary Fibrosis. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministry of Health and Welfare, National Research Foundation of Korea.
Abstract (Originalsprache)
Rationale
Although a relationship between the growth arrest-specific 6 (GAS6)/anexelekto (AXL) pathway and pulmonary fibrosis has been suggested, the precise mechanisms and clinical implications of the AXL pathway in idiopathic pulmonary fibrosis are still unclear.
Methods
Constitutive and conditional AXL-knockout mice were generated and injected with bleomycin to induce pulmonary fibrosis. The expression of AXL and macrophage subtypes in bleomycin-injected mice and patients with idiopathic pulmonary fibrosis was analysed using flow cytometry. The therapeutic effects of the AXL inhibitors were examined.
Results
AXL-deficient mice were resistant to bleomycin-induced pulmonary fibrosis and had a lower degree of M2-like macrophage differentiation than wild-type mice. Interestingly, AXL expression in monocytes was enhanced according to the progression of bleomycin-induced pulmonary fibrosis, and these results were especially prominent in lymphocyte antigen 6C (Ly6C) high monocytes. Gene silencing or inhibitor treatment with AXL inhibited the differentiation of M2-like macrophages during bone marrow-derived macrophage differentiation. These results were confirmed through experiments using AXL fl/fl LysMCre+ mice and systems with depletion and reconstitution of macrophages. In line with these results, patients with severe idiopathic pulmonary fibrosis had high AXL expression in monocytes, high GAS6 levels and an enhanced population of M2-like macrophages compared to those with mild idiopathic pulmonary fibrosis. Lastly, treatment with AXL inhibitors ameliorated bleomycin-induced pulmonary fibrosis and improved survival rates.
Conclusions
The AXL pathway in classical monocytes contributes to pulmonary fibrosis progression through the induction of M2-like macrophage differentiation. Therefore, targeting AXL may be a promising therapeutic option for pulmonary fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
- D.H. Kim, H.C. Kim and K. Im contributed equally to this work.
- Department of Pulmonology and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
- Department of Cell and Genetic Engineering, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
- Department of Biochemistry and Molecular Biology, Brain Korea 21 Project, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
- Department of Convergence Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Förderung
- Ministry of Health and Welfare
- National Research Foundation of Korea
Zitieren
APA
Kim, D. H., Kim, H. C., Im, K., Baek, I. J., Choi, Y. J., Lee, H., Kim, D. S., Lee, C. W., Jeong, J., Ban, K., Kim, S. Y., Ji, W., Lee, J. C., Kim, H. Y., Lee, Y., Yang, Y., Yun, M., Choi, C. M., & Rho, J. K. (2025). Inhibition of AXL ameliorates pulmonary fibrosis via attenuation of M2 macrophage polarisation. European Respiratory Journal, 65(6), 2400615. https://doi.org/10.1183/13993003.00615-2024
Vancouver
Kim DH, Kim HC, Im K, Baek IJ, Choi YJ, Lee H, et al. Inhibition of AXL ameliorates pulmonary fibrosis via attenuation of M2 macrophage polarisation. European Respiratory Journal. 2025;65(6):2400615. doi:10.1183/13993003.00615-2024
BibTeX
@article{Kim2025,
author = {Kim, Dong Ha and Kim, Ho Cheol and Im, Kyungtaek and Baek, In-Jeoung and Choi, Yun Jung and Lee, Hyeonjeong and Kim, Da-Som and Lee, Chae Won and Jeong, JaeYi and Ban, Kyosun and Kim, Sang-Yeob and Ji, Wonjun and Lee, Jae Cheol and Kim, Hyun-Yi and Lee, Yoonji and Yang, Yeongin and Yun, Miyong and Choi, Chang Min and Rho, Jin Kyung},
title = {Inhibition of AXL ameliorates pulmonary fibrosis via attenuation of M2 macrophage polarisation},
journal = {European Respiratory Journal},
year = {2025},
volume = {65},
number = {6},
pages = {2400615},
doi = {10.1183/13993003.00615-2024}
}
EUVIMED